XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 169,878 $ 131,329
Marketable securities 359,775 510,094
Interest receivable 807 1,035
Accounts receivable 6,882 5,224
Prepaid expenses and other current assets 16,722 11,986
Total current assets 554,064 659,668
Marketable securities, non-current 49,205 50,530
Property and equipment, net 49,588 41,324
Intangible assets 56,298 58,128
Goodwill 41,501 42,798
Operating lease right-of-use assets 68,304 71,045
Other non-current assets 14,903 13,557
Restricted cash 1,500 1,500
Total assets 835,363 938,550
Current liabilities:    
Accounts payable 10,132 12,553
Accrued compensation and employee benefits 17,406 20,738
Other accrued liabilities 15,448 18,612
Deferred revenues 93,957 91,644
Total current liabilities 136,943 143,547
Deferred revenues, non-current 201,251 245,045
Long-term portion of lease liabilities 37,328 38,396
Deferred income tax 6,959 7,185
Other non-current liabilities 7,425 7,011
Total liabilities 389,906 441,184
Commitments
Stockholders’ equity:    
Preferred stock 0 0
Common stock 1,451 1,421
Additional paid-in capital 1,313,102 1,269,375
Accumulated deficit (871,083) (777,981)
Accumulated other comprehensive income 1,987 5,419
Total Sangamo Therapeutics, Inc. stockholders’ equity 445,457 498,234
Non-controlling interest 0 (868)
Total stockholders’ equity 445,457 497,366
Total liabilities and stockholders’ equity $ 835,363 $ 938,550